Toshio Matsumoto
Overview
Explore the profile of Toshio Matsumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
4736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferraz I, Carioca F, Junqueira F, Oliveira M, Duarte G, Foronda F, et al.
Pediatr Pulmonol
. 2024 Sep;
59(12):3593-3600.
PMID: 39267444
Background: Positive end-expiratory pressure (PEEP) is widely used to improve oxygenation and avoid alveolar collapse in mechanically ventilated patients with pediatric acute respiratory distress syndrome (PARDS). However, its improper use...
2.
Junqueira F, Ferraz I, Campos F, Matsumoto T, Brandao M, Nogueira R, et al.
Respir Care
. 2024 Jul;
69(11):1409-1416.
PMID: 39013568
Background: PEEP is a cornerstone treatment for children with pediatric ARDS. Unfortunately, its titration is often performed solely by evaluating oxygen saturation, which can lead to inadequate PEEP level settings...
3.
Kanai M, Ganbaatar B, Endo I, Ohnishi Y, Teramachi J, Tenshin H, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38891908
Chronic inflammation causes muscle wasting. Because most inflammatory cytokine signals are mediated via TGF-β-activated kinase-1 (TAK1) activation, inflammatory cytokine-induced muscle wasting may be ameliorated by the inhibition of TAK1 activity....
4.
Taguchi T, Matsushima H, Kodama S, Okubo N, Ito T, Ludwikowska M, et al.
Expert Opin Pharmacother
. 2024 Apr;
25(3):325-334.
PMID: 38588537
Background: Hormone therapy with aromatase inhibitors (AIs) for estrogen receptor-dependent breast cancer may expose patients to an increased osteoporosis risk. This study was performed to estimate fracture risk in women...
5.
Matsushima H, Taguchi T, Kodama S, Okubo N, Saito K, Jablonska K, et al.
J Bone Miner Metab
. 2024 Mar;
42(2):223-232.
PMID: 38493435
Introduction: Androgen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The...
6.
Sawatsubashi S, Takashi Y, Endo I, Kondo T, Abe M, Matsumoto T, et al.
Bone
. 2024 Feb;
182:117057.
PMID: 38412893
Excessive actions of FGF23 cause several kinds of hypophosphatemic rickets/osteomalacia. It is possible that there still remain unknown causes or mechanisms for FGF23-related hypophosphatemic diseases. We report two male cousins...
7.
Ranieri M, Angelini I, DAgostino M, Di Mise A, Centrone M, Venneri M, et al.
J Physiol
. 2024 Feb;
602(13):3207-3224.
PMID: 38367250
High concentrations of urinary calcium counteract vasopressin action via the activation of the Calcium-Sensing Receptor (CaSR) expressed in the luminal membrane of the collecting duct cells, which impairs the trafficking...
8.
Hiasa M, Endo I, Matsumoto T
J Bone Miner Metab
. 2024 Feb;
42(4):447-454.
PMID: 38324177
Positive regulators of bone formation, such as mechanical loading and PTH, stimulate and negative regulators, such as aging and glucocorticoid excess, suppress IL-11 gene transcription in osteoblastic cells. Signal transduction...
9.
Redivo J, Kannan H, Souza A, Junior J, Kudchadkar S, Horigoshi N, et al.
Crit Care Sci
. 2023 Dec;
35(3):290-301.
PMID: 38133159
Objective: To determine the prevalence and factors associated with the physical rehabilitation of critically ill children in Brazilian pediatric intensive care units. Methods: A 2-day, cross-sectional, multicenter point prevalence study...
10.
Sone T, Ohnaru K, Sugai T, Yamashita A, Okimoto N, Inoue T, et al.
Arch Osteoporos
. 2023 Nov;
18(1):146.
PMID: 38030806
Purpose: Abaloparatide (ABL) increased bone mineral density (BMD) in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial. To evaluate the effect of ABL on hip geometry...